PARP1-siRNA suppresses human prostate cancer cell growth and progression

Lai,Yongchang; Kong,Zhenzhen; Zeng,Tao; Xu,Shaohong; Duan,Xiaolu; Li,Shujue; Cai,Chao; Zhao,Zhijian; Wu,Wenqi

doi:10.3892/or.2018.6238

PARP1-siRNA suppresses human prostate cancer cell growth and progression

Authors:
- Yongchang Lai
- Zhenzhen Kong
- Tao Zeng
- Shaohong Xu
- Xiaolu Duan
- Shujue Li
- Chao Cai
- Zhijian Zhao
- Wenqi Wu
View Affiliations

Affiliations: Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Urology Research Institute, Guangdong Key Laboratory of Urology, Guangzhou 510230, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/or.2018.6238
Pages: 1901-1909

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. However, since PARP inhibitors (PARPi) mainly modulate the activation of PARP but not its expression, whether small interfering RNA (siRNA) specific to PARP has the same function as PARPi has not been well defined. In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation. PARP1 silencing could significantly inhibit PC3 cell migration and invasion. Additionally, PARP1-siRNA also inhibited the proliferation of PC3 and Du145 cells. After the induction of apoptosis by docetaxel, cleaved-caspase3 of DU145 and C4-2 cells increased significantly in the PARP1-siRNA group. In the xenograft nude mouse model, PARP1-siRNA could suppress xenograft tumor size of PC3 cells and produce a more regular morphology. In vitro and in vivo, PARP1 silencing significantly downregulated vimentin expression and upregulated E-cadherin expression, both of which are epithelial-mesenchymal transition (EMT) markers. It has been revealed that PI3K inhibition could sensitize the effect of PARPi. Notably, PARP1-siRNA could suppress the expression of EGFR and p-GSK3β (Ser9) in PCa cells, which was different from PARPi. Our results indicated that PARP1-siRNA can suppress the growth and invasion capacity of PCa cells, thereby suggesting that PARP1-siRNA, which is different from PARPi, may provide a potential treatment method for PCa.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, et al: Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 13:506–521. 2017. View Article : Google Scholar : PubMed/NCBI
3	Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, et al: Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 543:1162017. View Article : Google Scholar
4	Lin KY and Kraus WL: PARP Inhibitors for cancer therapy. Cell. 169:1832017. View Article : Google Scholar : PubMed/NCBI
5	Ray Chaudhuri A and Nussenzweig A: The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 18:610–621. 2017. View Article : Google Scholar : PubMed/NCBI
6	Schiewer MJ and Knudsen KE: Transcriptional roles of PARP1 in cancer. Mol Cancer Res. 12:1069–1080. 2014. View Article : Google Scholar : PubMed/NCBI
7	Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, et al: Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 8:3742017. View Article : Google Scholar : PubMed/NCBI
8	Ning J, Wakimoto H, Peters C, Martuza RL and Rabkin SD: Rad51 degradation: Role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 109:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wu W, Zhu H, Liang Y, Kong Z, Duan X, Li S, Zhao Z, Yang D and Zeng G: Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients. Int Urol Nephrol. 46:1345–1349. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wu W, Kong Z, Duan X, Zhu H, Li S, Zeng S, Liang Y, Iliakis G, Gui Z and Yang D: Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. Biochem Biophys Res Commun. 442:127–132. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lee JY and Kong G: Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci. 73:4643–4660. 2016. View Article : Google Scholar : PubMed/NCBI
12	Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, et al: Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 23:1156–1164. 2012. View Article : Google Scholar : PubMed/NCBI
13	Donizy P, Pietrzyk G, Halon A, Kozyra C, Gansukh T, Lage H, Surowiak P and Matkowski R: Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up. Oncol Rep. 31:1777–1787. 2014. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Zhang Y, Zhao Y, Gao D, Xing J and Liu H: High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer. Oncol Lett. 12:3825–3835. 2016. View Article : Google Scholar : PubMed/NCBI
15	Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, Bosco P, Castiglione R and Salemi M: PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 56:e92012. View Article : Google Scholar : PubMed/NCBI
16	Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J and Bartek J: DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol. 10:879–894. 2016. View Article : Google Scholar : PubMed/NCBI
17	Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, et al: Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-Mutant ovarian cancer. Cell Rep. 14:429–439. 2016. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F and Johnson N: RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest. 126:3145–3157. 2016. View Article : Google Scholar : PubMed/NCBI
19	Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang Y, Xiao H, Zhang D and Jiang J: Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett. 389:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
20	Chaudhry P, Fabi F, Singh M, Parent S, Leblanc V and Asselin E: Prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition. Cell Death Dis. 5:e10442014. View Article : Google Scholar : PubMed/NCBI
21	Pu H, Horbinski C, Hensley PJ, Matuszak EA, Atkinson T and Kyprianou N: PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis. 35:2592–2601. 2014. View Article : Google Scholar : PubMed/NCBI
22	Day KC, Lorenzatti Hiles GL, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunja LP, Hall C, Palanisamy N, et al: HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 77:74–85. 2017. View Article : Google Scholar : PubMed/NCBI
23	Liu XL, Zhang XT, Meng J, Zhang HF, Zhao Y, Li C, Sun Y, Mei QB, Zhang F and Zhang T: ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget. 8:54265–54276. 2017.PubMed/NCBI
24	El Bezawy R, Cominetti D, Fenderico N, Zuco V, Beretta GL, Dugo M, Arrighetti N, Stucchi C, Rancati T, Valdagni R, et al: miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Lett. 395:53–62. 2017. View Article : Google Scholar : PubMed/NCBI
25	Kim GT, Lee SH and Kim YM: Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways. Int J Oncol. 45:1673–1679. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wei A, Fan B, Zhao Y, Zhang H, Wang L, Yu X, Yuan Q, Yang D and Wang S: ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway. Oncotarget. 7:65374–65388. 2016. View Article : Google Scholar : PubMed/NCBI
27	Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D, et al: Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 7:416562017. View Article : Google Scholar : PubMed/NCBI
28	Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, et al: PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 23:3711–3720. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang J, Kho DH, Zhou JY, Davis RJ and Wu GS: MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance. Oncogene. 36:5939–5947. 2017. View Article : Google Scholar : PubMed/NCBI
30	Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, et al: Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2:1134–1149. 2012. View Article : Google Scholar : PubMed/NCBI